eIF4E Inhibitors for Selective TFH Cell Suppression

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies lack specific pharmacologic inhibitors for T Follicular Helper (TFH) cells, which are implicated in autoimmune diseases like Multiple Sclerosis, and the regulation of TFH cell differentiation and activity remains poorly understood, particularly at the level of mRNA translation.

Innovation Solution

Administration of eukaryotic translation initiation factor 4E (eIF4E) inhibitors, such as 4EGI-1, to selectively downregulate TFH cell differentiation and activity without affecting other T cell types, using small molecule drugs or interfering RNAs to target eIF4E and inhibit TFH cell lineage-determining mRNAs.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current therapies are used to treat autoimmune diseases, then general immune suppression may be achieved, but specific inhibition of TFH cells is not possible and other T cell types are also affected

Engineering Contradiction:

Improvespecificity of TFH cell inhibitionVSAvoidoff-target effects on other T cell types

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent applies local quality by targeting a specific molecular mechanism (eIF4E translation initiation factor) that is selectively required for TFH cell differentiation and function, rather than using broad immune suppression. This selective targeting at the molecular level allows inhibition of TFH cells while preserving other T cell types, achieving both specificity and functional selectivity.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent utilizes parameter changes by modulating the activity of eIF4E, a key translation initiation factor, to control TFH cell differentiation. By changing the functional state of eIF4E through pharmacologic inhibition, the patent achieves selective control over TFH cell development without affecting other T cell lineages, thereby resolving the contradiction between specificity and harmful off-target effects.

Inventive Principle:

Principle #35Parameter changes

2Object-affected harmful factors

If broad immune suppression therapies are used, then autoimmune responses are reduced, but immune function and other T cell types are compromised

Engineering Contradiction:

Improveautoimmune pathogenesisVSAvoidpreservation of immune function

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent extracts the harmful TFH cell-mediated autoimmune response from the broader T cell population by targeting a specific molecular mechanism (eIF4E) that is selectively required for TFH differentiation. This extraction allows suppression of autoimmune pathogenesis while leaving other T cell types and immune functions intact, resolving the contradiction between reducing harm and preserving function.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent applies local quality by directing therapeutic intervention specifically at the molecular level (eIF4E) that drives TFH cell differentiation, rather than applying broad immune suppression. This localized molecular targeting enables selective inhibition of autoimmune mechanisms while preserving overall immune function and other T cell lineages.

Inventive Principle:

Principle #3Local quality

3Reliability

If TFH cell differentiation is inhibited, then autoimmune disease is prevented, but the mechanism of mRNA translation regulation is not well understood

Engineering Contradiction:

Improveinhibition of TFH cell differentiationVSAvoidunderstanding of translation regulation

Core Design Contradiction:

ReliabilityVSLoss of information

Solution Approach 1:

The patent identifies eIF4E as an intermediary molecular factor that mediates TFH cell differentiation through regulation of mRNA translation. By targeting eIF4E as a pharmacologic intervention point, the patent achieves reliable inhibition of TFH differentiation while simultaneously uncovering critical information about translation regulation mechanisms, thereby resolving the contradiction between therapeutic efficacy and mechanistic understanding.

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Partial inhibition of eIF4E effectively inhibits TFH cell-mediated autoimmune pathogenesis, preventing or reversing autoimmune disorders by reducing TFH cell development and function, as demonstrated in animal models of multiple sclerosis and other autoimmune diseases, without disrupting other T cell types.

Implementation Method 1

eukaryotic translation initiation factor 4E (eIF4E) inhibitors to inhibit TFH cell-mediated differentiation and/or activation

Methodology Applied

Scientific EffectTranslation initiation inhibition:

Data Source

PatentUS12168003B2Selective inhibition of T follicular helper cells for treatment of autoimmune disorders

Publication Date: 2024.12.17 NEW YORK UNIV

AI summary

Disclosed herein is a method of inhibiting T Follicular Helper (TFH) cell-mediated differentiation and/or activation in a subject. This method involves administering to a subject in need of treatment for an autoimmune disorder a eukaryotic translation initiation factor 4E (eIF4E) inhibitor to inhibit TFH cell-mediated differentiation and/or activation in the subject. Also disclosed is a method of inhibiting T Follicular Helper (THF) cell differentiation or TFH cell activity.